Request of a first touch point with VCs to align our strategy and postpone the pre-clinical certified phase final quote

ADA is a startup developing nanomedicine-based inhaled therapies for the treatments of chronic respiratory diseases. On one side, we obtained very promising in-vivo efficacy results for the systemic sclerosis with interstitial lung disease bleomicin model and we are currently conducting a test against oral nintedanib which is the standard of care. This project exploits a self-assembling platform to combine both carrier and therapeutic effects. On the other side, we got positive in-vitro results for the idiopathic pulmonary fibrosis test with a molecule that acts on a different target of the interstitial lung disease pathway. Our next (already financed) step considers a combination of the two projects together to beat the standard of care with a full proprietary solution. Based on the upcoming endpoints, we are outlining different strategies with several contract research organizations. Their current inputs imply an initial regulatory strategy quote which prevents us now to correctly quantify the required amount to finalize the pre-clinical certified phase until we do not identify the right partner to work with. That’s why we would like to establish a contact with the interested VCs giving us the possibility to postpone the discussion on the correct amount that comes from the regulatory analysis which is expected to end in the next few months.